| Autor: |
Cohen, Elisabeth, Bozonnat, Alizée, Battistella, Maxime, Calvani, Julien, Vignon‐Pennamen, Marie‐Dominique, Rivet, Jacqueline, Moins‐Teisserenc, Hélène, Ta, Van‐Anh, Ram‐Wolff, Caroline, Bouaziz, Jean‐David, Mahevas, Thibault, Bagot, Martine, Mourah, Samia, Louveau, Baptiste, Sicre de Fontbrune, Flore, Peffault de Latour, Regis, de Masson, Adèle, Battesti, Gilles |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jan2024, Vol. 38 Issue 1, pe32-e34, 3p |
| Abstrakt: |
This article discusses two cases of patients with cutaneous T-cell lymphoma (CTCL) who experienced severe relapses after receiving ruxolitinib, a JAK1/2 inhibitor, for the treatment of graft-versus-host disease (GVHD) following allogeneic stem cell transplantation (allo-HSCT). The patients initially showed positive responses to ruxolitinib for GVHD, but their CTCL worsened, leading to erythroderma and skin tumors. The authors suggest that ruxolitinib may have a deleterious effect on CTCL after allo-HSCT, possibly impairing the graft versus leukemia (GVL) response. Further investigation is needed to evaluate the use of JAK inhibitors in CTCL treatment after allo-HSCT. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text